Expression of metastasis associated proteins, CD44v6 and NM23-H1, in pediatric acute lymphoblastic leukemia

E. Magyarosy, A. Sebestypén, J. Tímár

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Two metastasis-associated proteins, CD44v6 and NM23-H1, are expressed by normal lymphoid cells, the former serving as activation marker and the latter as a constitutive protein. CD44v6 is considered as a marker of poor prognosis of various hematological cancers but its expression was not demonstrated in childhood acute lymphoblastic leukaemia (ALL). On the other hand, NM23-H1 is considered as a differentiation inhibitory factor in various hematological cancers and as a marker of poor prognosis. Therefore we analyzed the expression of CD44v6 and NM23-H1 in the bone marrow of sixteen pediatric ALL patients using immunocytochemistry. For the first time, we have demonstrated the expression of CD44v6 protein epitopes on leukemic cells in a proportion of ALL cases (6 out of 16), primarily in the medium/high risk group (except one case), suggesting a possible association to an unfavourable outcome. On the other hand, NM23-H1 protein expression was maintained in leukaemic cells in 50% of both low and medium/high risk ALL cases. The majority of the pediatric ALL cases expressed only one of the metastasis-associated proteins (10 out of 16). This feature is similar to the observations made in several adult solid cancers. The potential of CD44v6 expression in leukaemic cells as prognosticator in pediatric ALL should be evaluated in a larger clinical trial.

Original languageEnglish
Pages (from-to)819-823
Number of pages5
JournalAnticancer Research
Volume21
Issue number1 B
Publication statusPublished - 2001

Fingerprint

Precursor Cell Lymphoblastic Leukemia-Lymphoma
Pediatrics
Neoplasm Metastasis
Proteins
Neoplasms
Epitopes
Bone Marrow
Immunohistochemistry
Clinical Trials
Lymphocytes

Keywords

  • ALL
  • CD44v6
  • NM23-H1
  • Risk groups

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Expression of metastasis associated proteins, CD44v6 and NM23-H1, in pediatric acute lymphoblastic leukemia. / Magyarosy, E.; Sebestypén, A.; Tímár, J.

In: Anticancer Research, Vol. 21, No. 1 B, 2001, p. 819-823.

Research output: Contribution to journalArticle

@article{27c4e3ce5f4d4e6d9cc49a8f8b2aa95b,
title = "Expression of metastasis associated proteins, CD44v6 and NM23-H1, in pediatric acute lymphoblastic leukemia",
abstract = "Two metastasis-associated proteins, CD44v6 and NM23-H1, are expressed by normal lymphoid cells, the former serving as activation marker and the latter as a constitutive protein. CD44v6 is considered as a marker of poor prognosis of various hematological cancers but its expression was not demonstrated in childhood acute lymphoblastic leukaemia (ALL). On the other hand, NM23-H1 is considered as a differentiation inhibitory factor in various hematological cancers and as a marker of poor prognosis. Therefore we analyzed the expression of CD44v6 and NM23-H1 in the bone marrow of sixteen pediatric ALL patients using immunocytochemistry. For the first time, we have demonstrated the expression of CD44v6 protein epitopes on leukemic cells in a proportion of ALL cases (6 out of 16), primarily in the medium/high risk group (except one case), suggesting a possible association to an unfavourable outcome. On the other hand, NM23-H1 protein expression was maintained in leukaemic cells in 50{\%} of both low and medium/high risk ALL cases. The majority of the pediatric ALL cases expressed only one of the metastasis-associated proteins (10 out of 16). This feature is similar to the observations made in several adult solid cancers. The potential of CD44v6 expression in leukaemic cells as prognosticator in pediatric ALL should be evaluated in a larger clinical trial.",
keywords = "ALL, CD44v6, NM23-H1, Risk groups",
author = "E. Magyarosy and A. Sebestyp{\'e}n and J. T{\'i}m{\'a}r",
year = "2001",
language = "English",
volume = "21",
pages = "819--823",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "1 B",

}

TY - JOUR

T1 - Expression of metastasis associated proteins, CD44v6 and NM23-H1, in pediatric acute lymphoblastic leukemia

AU - Magyarosy, E.

AU - Sebestypén, A.

AU - Tímár, J.

PY - 2001

Y1 - 2001

N2 - Two metastasis-associated proteins, CD44v6 and NM23-H1, are expressed by normal lymphoid cells, the former serving as activation marker and the latter as a constitutive protein. CD44v6 is considered as a marker of poor prognosis of various hematological cancers but its expression was not demonstrated in childhood acute lymphoblastic leukaemia (ALL). On the other hand, NM23-H1 is considered as a differentiation inhibitory factor in various hematological cancers and as a marker of poor prognosis. Therefore we analyzed the expression of CD44v6 and NM23-H1 in the bone marrow of sixteen pediatric ALL patients using immunocytochemistry. For the first time, we have demonstrated the expression of CD44v6 protein epitopes on leukemic cells in a proportion of ALL cases (6 out of 16), primarily in the medium/high risk group (except one case), suggesting a possible association to an unfavourable outcome. On the other hand, NM23-H1 protein expression was maintained in leukaemic cells in 50% of both low and medium/high risk ALL cases. The majority of the pediatric ALL cases expressed only one of the metastasis-associated proteins (10 out of 16). This feature is similar to the observations made in several adult solid cancers. The potential of CD44v6 expression in leukaemic cells as prognosticator in pediatric ALL should be evaluated in a larger clinical trial.

AB - Two metastasis-associated proteins, CD44v6 and NM23-H1, are expressed by normal lymphoid cells, the former serving as activation marker and the latter as a constitutive protein. CD44v6 is considered as a marker of poor prognosis of various hematological cancers but its expression was not demonstrated in childhood acute lymphoblastic leukaemia (ALL). On the other hand, NM23-H1 is considered as a differentiation inhibitory factor in various hematological cancers and as a marker of poor prognosis. Therefore we analyzed the expression of CD44v6 and NM23-H1 in the bone marrow of sixteen pediatric ALL patients using immunocytochemistry. For the first time, we have demonstrated the expression of CD44v6 protein epitopes on leukemic cells in a proportion of ALL cases (6 out of 16), primarily in the medium/high risk group (except one case), suggesting a possible association to an unfavourable outcome. On the other hand, NM23-H1 protein expression was maintained in leukaemic cells in 50% of both low and medium/high risk ALL cases. The majority of the pediatric ALL cases expressed only one of the metastasis-associated proteins (10 out of 16). This feature is similar to the observations made in several adult solid cancers. The potential of CD44v6 expression in leukaemic cells as prognosticator in pediatric ALL should be evaluated in a larger clinical trial.

KW - ALL

KW - CD44v6

KW - NM23-H1

KW - Risk groups

UR - http://www.scopus.com/inward/record.url?scp=0035065147&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035065147&partnerID=8YFLogxK

M3 - Article

C2 - 11299850

AN - SCOPUS:0035065147

VL - 21

SP - 819

EP - 823

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 1 B

ER -